CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Charles River Laboratories International (NYSE: CRL)
›
Charles River Laboratories International (NYSE: CRL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 18,300 employees.
The shares were at 327.93 USD on 19 November 2026, up 95.4% over 52 weeks. Its 52-week range is 146.20 USD to 379.63 USD: the price is 13.6% below the high and 124.3% above the low.
At a market capitalisation of 15.71B USD, it trades at 356.4 times trailing earnings and 25.3 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 922% for CRL.
Charles River Laboratories International reports return on equity of -4.6%, an operating margin of 14.3% and revenue down 2.2% year over year.
Its debt exceeds its cash by 2.65B USD, a debt-to-equity ratio of 0.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 350.57 USD is 6.9% above the current price. The next earnings report is expected on 17 February 2027.